INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IV EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) FOR THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE

Registry ID

19356A (PROSPECT-2)

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

H. LUNDBECK A/S

Start date

2023-05-01

Last update

2022-03-04

Conditions

• CHRONIC MIGRAINE

Related clinical trials

• A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ESCALATION AND DOSE FINDING PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPN10200 IN THE PREVENTION OF EPISODIC OR CHRONIC MIGRAINE IN ADULTS (MERANTI)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL WITH EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF XEOMIN® INJECTIONS FOR THE PREVENTION OF CHRONIC MIGRAINE
• A PHASE 3, MULTICENTER, 12-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ATOGEPANT FOR THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE IN PEDIATRIC SUBJECTS 12 TO 17 YEARS OF AGE
• A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PARALLEL-GROUP STUDY WITH EXTENSION PHASE TO EVALUATE THE EFFICACY AND SAFETY OF DYSPORT® FOR THE PREVENTION OF CHRONIC MIGRAINE IN ADULT PARTICIPANTS
• LONG TERM, OPEN LABEL (DOSE BLINDED), EXTENSION STUDY OF EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH CHRONIC OR EPISODIC MIGRAINE
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY, SAFETY, AND TOLERABILITY OF SUBCUTANEOUS ADMINISTRATION OF FREMANEZUMAB VERSUS PLACEBO FOR THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE IN PEDIA

View on source registry